Corcept Therapeutics Incorporated (BIT:1CORT)

Corcept Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	133.66	141.21	106.14	101.42	112.51	106.01
Depreciation & Amortization	1.89	1.34	2.36	3.45	3.48	2.24
Loss (Gain) From Sale of Investments	-8.06	-10.94	-9.13	1.38	-	-
Stock-Based Compensation	73.75	61.35	48.94	42.44	42.93	33.54
Other Operating Activities	-50.53	-40.19	-29.49	-33.91	9.44	15.54
Change in Accounts Receivable	-10.73	-12.85	-10.07	-3.43	-1.43	-6.27
Change in Inventory	-3.02	0.31	1.27	1.2	3.44	-3.51
Change in Accounts Payable	4.17	-2.25	5.78	4.76	-3.6	3.16
Change in Income Taxes	3.74	3.78	1.21	8.69	0.01	0.01
Change in Other Net Operating Assets	37.33	56.32	10.03	-5.67	1.1	1.25
Operating Cash Flow	182.19	198.07	127.04	120.32	167.89	151.97
Operating Cash Flow Growth	47.24%	55.91%	5.58%	-28.33%	10.48%	11.65%
Capital Expenditures	-1.92	-2.17	-0.14	-0.41	-0.47	-1.24
Investment in Securities	-39.52	-175.43	91.05	-113.91	136.6	-118.03
Investing Cash Flow	-41.44	-177.6	90.91	-114.33	136.13	-119.26
Issuance of Common Stock	20.66	9.62	5.81	4.38	16.23	23.23
Repurchase of Common Stock	-189.05	-37.97	-154.53	-21.67	-318.82	-11.01
Financing Cash Flow	-168.39	-28.35	-148.72	-17.28	-302.59	12.21
Net Cash Flow	-25.84	-7.89	69.22	-11.29	1.43	44.92
Free Cash Flow	180.27	195.9	126.9	119.91	167.42	150.73
Free Cash Flow Growth	46.22%	54.37%	5.83%	-28.38%	11.07%	11.63%
Free Cash Flow Margin	25.17%	29.02%	26.31%	29.84%	45.75%	42.59%
Free Cash Flow Per Share	1.52	1.73	1.14	1.03	1.33	1.21
Cash Income Tax Paid	60.27	60.27	47.6	39.75	9.1	10.86
Levered Free Cash Flow	166.88	183.85	128.39	115.55	120.18	116.42
Unlevered Free Cash Flow	166.88	183.85	128.39	115.55	120.18	116.42
Change in Working Capital	31.49	45.3	8.22	5.54	-0.47	-5.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.